GFAP, UCH-L1, TAU AND NFL as potential biomarkers for glioblastoma diagnosis and monitoring: A retrospective study

Résumé fourni par la source

Introduction: Glioblastoma (GBM) is a highly aggressive brain cancer with rapid progression and limited treatment options, leading to a poor prognosis for most patients. Currently, no validated biomarkers exist for the accurate diagnosis and monitoring of GBM, which poses a significant challenge in clinical management. Liquid biopsies offer a minimally invasive alternative to traditional tissue biopsies and hold promise for improving GBM detection and monitoring. Identifying reliable biomarkers through liquid biopsies could transform GBM management by enabling earlier detection, precise monitoring of disease progression, and real-time assessment of therapeutic response, ultimately enhancing patient outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.